Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Sangamo Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 18, 2020 / 12:00PM GMT
Release Date Price: $11.43
Zeeshan Merchant;Morgan Stanley;Executive Director

Hello, everyone. This is Zeeshan Merchant from Morgan Stanley. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you're a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. This session is for the fireside chat for Sangamo. With me today, I am joined by CEO, Sandy Macrae.

And with that, I will turn it over to Sandy to briefly introduce the company.

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Good morning, Zeeshan, and good morning, everyone. It's a pleasure to be with you. I joined Sangamo in 2016, and Sangamo is a fascinating company. It truly is a leading genomic medicine company. And we have programs in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot